Sylatron FDA Approval History
FDA Approved: Yes (First approved March 29, 2011)
Brand name: Sylatron
Generic name: peginterferon alfa-2b
Treatment for: Melanoma
Sylatron (peginterferon alfa-2b) is an alpha interferon indicated for the adjuvant treatment of melanoma.
Development Timeline for Sylatron
|Apr 12, 2011||FDA Approves Merck's Sylatron (peginterferon alfa-2b) for Injection, a New Adjuvant Treatment for Melanoma with Microscopic or Gross Nodal Involvement|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.